SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis
VACOVAJI
SARS Cov2 Vaccination in Adolescents From 12 to 18 With Juvenile Idiopathic Arthritis in Angers, Nantes and Rennes : Acceptance and Safety.
1 other identifier
observational
200
1 country
1
Brief Summary
Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and well tolerated. It has been shown previously that this population has a vaccine coverage lower than the global population even though few datas are available on this topic The aim of this resarch is to study the vaccination coverage against the SARS-Cov2 virus and more specifically the reasons why adolescents were or were not vaccinated in the population of adolescents with juvenile arthitis followed up in Angers, Nantes and Rennes. For this purpose, a review of the medical record will be done and a questionnaire will be adressed to the family of patients in order to collect informations about the disease, the treatments, the motives or obstacles to vaccination. Secondaries end points are safety of the vaccination, consequences on the juvenile arthritis (such as changes in the medication, flare-up of the illness) and the occurence of covid infection after vaccination.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 12, 2022
CompletedFirst Posted
Study publicly available on registry
September 21, 2022
CompletedStudy Start
First participant enrolled
June 9, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedJune 21, 2024
June 1, 2024
1.1 years
September 12, 2022
June 20, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
SARS Cov2 vaccination coverage of this population and factors influencing the realization of the vaccination.
Percentage of patients vaccinated
From june 2021 to December 2022
Secondary Outcomes (3)
Tolerance of the SARS-Cov2 vaccination
From june 2021 to December 2022
Effect of the SARS Cov2 vaccination on juvenile arthritis
From june 2021 to December 2022
SARS-Cov 2 infection after vaccination
From june 2021 to December 2022
Study Arms (1)
Trial population
Children from 12 to 18 years old followed up for juvenile arthritis in Angers, Nantes and Rennes.
Eligibility Criteria
Patients from 12 to 18 years old followed up from juvenile arthritis in 2021 and 2022 at Angers, Nantes and Rennes.
You may qualify if:
- Patients from 12 to 18 years old, on January the 1st 2022
- Patients followed up from juvenile arthritis
- Patients followed up in 2021 and 2022
You may not qualify if:
- Patients under 12 years old.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Nantes University Hospitallead
- University Hospital, Angerscollaborator
- Rennes University Hospitalcollaborator
- Clinique de l'Anjoucollaborator
Study Sites (1)
CHU de Nantes
Nantes, Loire-Atlantique, 44300, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 12, 2022
First Posted
September 21, 2022
Study Start
June 9, 2024
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
June 21, 2024
Record last verified: 2024-06